2014 Research Grant Recipient

A Randomized Controlled Trial of Bevacizumab for HHT-Related Epistaxis

Amelia Clark MD

Cure HHT is pleased to announce that Dr. Amelia Clark from Stanford University School of Medicine has been awarded a $10,000 grant for her research entitled "A Randomized Controlled Trial of Bevacizumab for HHT-Related Epistaxis". The research performed is under the direction of the Principal Investigator Dr. Peter Hwang, Professor in the Department of Otolaryngology at Stanford and Director of the Division of Rhinology and Endoscopic Skull Base Surgery.

Dr. Clark received her medical degree from Mount Sinai School of Medicine in New York City. She is currently a Resident Physician in the Department of Otolaryngology - Head and Neck Surgery at Stanford University School of Medicine, where her research is focused on determining (1) if intranasal bevacizumab injection decreases nosebleed frequency and severity compared to placebo when used in conjunction with electrocautery for patients with HHT, as measured by the ESS scoring system; (2) if intranasal bevacizumab injection results in a greater improvement in quality of life compared to placebo when used in conjunction with electrocautery for patients with HHT; and (3) the cost-effectiveness of intranasal bevacizumab injection compared to placebo when used in conjunction with electrocautery for patients with HHT.

Cure HHT, in partnership with the American Academy of Otolaryngology, is funding this important research as a follow-up to the Cure HHT North American Study of Epistaxis (NOSE Study) in which the efficacy of four agents (i.e., Bevacizumab, Estriol, Tranexamic Acid, and Saline) were tested in the first large-scale multi-center clinical trial.

The Stanford Sinus Center at the Stanford School of Medicine is poised to carry out the first randomized, double-blind, placebo-controlled clinical trial of bevacizumab injection versus saline control for the management of HHT-related epistaxis, by which they hope to shift the current clinical practice paradigms in treating this debilitating disease.

To learn more about eligibility and participation requirements, click here.